Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note released on Thursday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ ADXS opened at $0.03 on Thursday. The stock has a market cap of $1.28 million, a P/E ratio of 0.00 and a beta of 1.24. The firm’s 50-day simple moving average is $0.03 and its 200 day simple moving average is $0.04. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.78.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.